Heather Poad
University of Leeds
7 Papers
28 Citations
Heather Poad is an academic researcher from University of Leeds. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 4, co-authored 4 publications.
Chat about Author
Papers
Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study
James W.F. Catto,Kathryn Gordon,Michelle Collinson,Heather Poad,Maureen Twiddy,Mark I. Johnson,Sunjay Jain,Rohit Chahal,Matt Simms,Mohantha Dooldeniya,Richard W. Bell,Phillip Koenig,Samantha Conroy,Louise Goodwin,Aidan P. Noon,Julie Croft,Julia Brown +16 more
TL;DR: A randomized controlled trial comparing mBCG and RC will be challenging to recruit into because around 10% of patients with high-risk HRNMIBC have a lethal disease and may be better treated by primary radical treatment.
84
Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study
Jamie B. Oughton,Heather Poad,Maureen Twiddy,Michelle Collinson,Victoria Hiley,Kathryn Gordon,Mark I. Johnson,Sunjay Jain,Aidan P. Noon,Rohit Chahal,Matt Simms,Mohantha Dooldeniya,Phillip Koenig,Louise Goodwin,Julia Brown,James W.F. Catto +15 more
TL;DR: BRAVO is a multi-centre, parallel-group, mixed-methods, individually randomised, controlled, feasibility study for patients with high-risk non-muscle invasive bladder cancer to demonstrate the feasibility and acceptability of performing the definitive phase III trial.
30
Randomised, double-blind, multicentre, mixed-methods, dose-escalation feasibility trial of mirtazapine for better treatment of severe breathlessness in advanced lung disease (BETTER-B feasibility)
Irene J Higginson,Andrew Wilcock,Miriam J. Johnson,Miriam J. Johnson,Sabrina Bajwah,Natasha Lovell,Deokhee Yi,Simon P. Hart,Simon P. Hart,Vincent Crosby,Heather Poad,David C. Currow,Emma Best,Sarah Brown +13 more
TL;DR: A randomised feasibility trial of mirtazapine over 28 days in adults with a modified medical research council breathlessness scale score ≥3 and most patients had COPD or interstitial lung disease found no differences between placebo and mirtzapine in tolerability or safety.
22
PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma
Hannah Buckley,Fiona Collinson,Gemma Ainsworth,Heather Poad,Louise Flanagan,Eszter Katona,Helen Howard,Geraldine Murden,Rosamonde E. Banks,Joanne Brown,Galina Velikova,Tom Waddell,Kate Fife,Paul Nathan,James Larkin,Thomas Powles,Sarah Brown,Naveen S. Vasudev +17 more
TL;DR: Modifying the frequency of ipilimumab dosing may mitigate toxicity rates and positively impact quality of life without compromising efficacy, a hypothesis being explored in other tumour types such as non-small cell lung cancer.
The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
TL;DR: In this article , the validity of surrogate endpoints in colorectal cancer has been investigated and it was found that the surrogate endpoint is stronger within some treatment classes compared to when ignoring the treatment class.